pin. Cell Biol 2005;17:141�?49. 12. Stoyanov B, Volinia S, Hanck T, Rubio I, Loubtchenkov M, Malek D, Stoyanova S, Vanhaesebroeck B, Dhand R, Nurnberg B, et al. Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Science 1995;269:690�?93. 13. Vanhaesebroeck B, PF-01367338 459868-92-9 Welham MJ, Kotani K, Stein R, Warne PH, Zvelebil MJ, Higashi K, Volinia S, Downward J, Waterfield MD. P110δ, a novel phosphoinositide 3-kinase in leukocytes. Proc. Natl. Acad. Sci. USA 1997;94:4330�?335. 14. Chantry D, Vojtek A, Kashishian A, Holtzman DA, Wood C, Gray PW, Cooper JA, Hoekstra MF. p110δ, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J. Biol. Chem 1997;272:19236�?9241. 15. Okkenhaug K, Vanhaesebroeck B.
PI3K in lymphocyte development, differentiation and activation. Nat. Rev. Immunol 2003;3:317�?30. 16. AS-252424 PI3K inhibitor Rommel C, Camps M, Ji H. PI3K δ and PI3K γ: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat. Rev. Immunol 2007;7:191�?01. 17. Ali K, Bilancio A, Thomas M, Pearce W, Gilfillan AM, Tkaczyk C, Kuehn N, Gray A, Giddings J, Peskett E, et al. Essential role for the p110δ phosphoinositide 3-kinase in the allergic response. Nature 2004;431:1007�?011. 18. Lee KS, Lee HK, Hayflick JS, Lee YC, Puri KD. Inhibition of phosphoinositide 3-kinase δ attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model. FASEB J 2006;20:455�?65. 19. Laffargue M, Calvez R, Finan P, Trifilieff A, Barbier M, Altruda F, Hirsch E, Wymann MP.
Phosphoinositide 3-kinase γ is an essential amplifier of mast cell function. Immunity 2002;16:441�?51. 20. Sadhu C, Masinovsky B, Dick K, Sowell CG, Staunton DE. Essential role of phosphoinositide 3-kinase δ in neutrophil directional movement. J. Immunol 2003;170:2647�?654. 21. Pomel V, Klicic J, Covini D, Church DD, Shaw JP, Roulin K, Burgat-Charvillon F, Valognes D, Camps M, Chabert C, et al. Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase γ. J. Med. Chem 2006;49:3857�?871. 22. Camps M, Ruckle T, Ji H, Ardissone V, Rintelen F, Shaw J, Ferrandi C, Chabert C, Gillieron C, Francon B, et al. Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med 2005;11:936�?43. 23.
Hirsch E, Katanaev VL, Garlanda C, Azzolino O, Pirola L, Silengo L, Sozzani S, Mantovani A, Altruda F, Wymann MP. Central role for G protein-coupled phosphoinositide 3-kinase γ in inflammation. Science 2000;287:1049�?053. 24. Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E, Pearce W, Meek SE, Salpekar A, Waterfield MD, et al. Impaired B and T cell antigen receptor signaling in p110δ PI 3-kinase mutant mice. Science 2002;297:1031�?034. 25. Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, et al. PI 3-kinase p110β: a new target for antithrombotic therapy. Nat. Med 2005;11:507�?14. 26. Jackson, SP. Preparation of morpholinyl- and pyridinyl-substituted heterobicyclic ketones as selective inhibitors of phosphoinositide 3-kinase β for use against thrombosis.
2004. International, WO 2003-IB4177, 2004 Ali et al. Page 9 J Immunol. Author manuscript; available in PMC 2009 February 16. UKPMC Funders Group Author Manuscript UKPMC Funders Group Author Manuscript 27. Sadhu C, Dick K, Tino WT, Staunton DE. Selective role of PI3K δ in neutrophil inflammatory responses. Biochem. Biophys. Res. Commun 2003;308:764�?69. 28. Puri KD, Doggett TA, Douangpanya J, Hou Y, Tino WT, Wilson T, Graf T, Clayton E, Turner M, Hayflick JS